Theratechnologies Stock Quote THTX - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.38

Bid

1.28

Ask

1.52

Volume

18,722

1.325 Day's Range 1.38

0.88 52 Week Range 4.30

Market Cap

63.452M

Previous Close

1.34

Open

1.38

Last Trade

1.34

Last Trade Time

16:00:00

Financial Volume

$ 25,365

VWAP

1.3548

Average Volume (3m)

35,203

Shares Outstanding

45,980,019

Dividend Yield

PE Ratio

-2.65

Earnings Per Share (EPS)

-0.52

Revenue

81.76M

Net Profit

-23.96M

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization... Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.theratech.com

Headquarters

Quebec City, Quebec, Can

Founded

1970

Theratechnologies Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker THTX. The last closing price for Theratechnologies was $1.34. Over the last year, Theratechnologies shares have traded in a share price range of $ 0.88 to $ 4.30.

Theratechnologies currently has 45,980,019 shares outstanding. The market capitalization of Theratechnologies is $63.45 million. Theratechnologies has a price to earnings ratio (PE ratio) of -2.65.

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

Q1 2024 consolidated revenue of $16.2 million Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA1FY2024 revenue guidance confirmed between $87 and $90 million and an...

U.S. Index Futures Show Mixed Trend Ahead of Key Inflation Data Release, Oil Prices Edge Higher

U.S. index futures are showing a mixed trend in Wednesday’s pre-market trading. Investors are eagerly awaiting fundamental US inflation data, which should provide crucial insights into the...

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft modelsSORT1 gene...

Theratechnologies Appoints Elina Tea to its Board of Directors

MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

MONTREAL, April 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers Separate data to highlight activity of sudocetaxel zendusortide (TH1902) to trigger...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.08	6.15384615385	1.3	1.38	1.28	8687	1.32475859	CS
4	0.04	2.98507462687	1.34	1.7	1.26	25351	1.47349119	CS
12	-0.29	-17.3652694611	1.67	1.77	1.16	35203	1.48266469	CS
26	-0.19	-12.101910828	1.57	2.58	0.88	106264	1.43408347	CS
52	-2.54	-64.7959183673	3.92	4.3	0.88	142339	1.93063352	CS
156	-12.34	-89.9416909621	13.72	17.8396	0.88	134156	6.83422702	CS
260	-13.78	-90.8970976253	15.16	17.8396	0.88	164454	8.60499679	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CSSEChicken Soup for the Soul Entertainment Inc	$ 0.2188 (43.66%)	5.87M
SHIMShimmick Corporation	$ 3.56 (16.91%)	252.04k
TSLTT Rex 2X Long Tesla Daily Target ETF	$ 8.48 (15.22%)	1.71M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 6.21 (15.21%)	7.48M
TSLRGraniteShares ETF Trust GraniteShares	$ 9.30 (14.67%)	225.26k
JYDJayud Global Logistics Ltd	$ 0.865 (-16.83%)	134.75k
TSDDGraniteShares ETF Trust GraniteShares	$ 29.75 (-16.20%)	123.82k
TSLZT Rex 2X Inverse Tesla Daily Target ETF	$ 47.21 (-15.58%)	502.48k
FRESFresh2 Group Ltd	$ 0.3988 (-15.15%)	153.6k
NCINeo Concept International Group Holdings Ltd	8.27 (-12.95%)	23.19k
TSLATesla Inc	$ 155.75 (7.65%)	16.92M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 6.21 (15.21%)	7.48M
CSSEChicken Soup for the Soul Entertainment Inc	$ 0.2188 (43.66%)	5.87M
SQQQProShares UltraPro Short QQQ	$ 11.80 (-0.92%)	3.83M
CYNCYNGN Inc	$ 0.1125 (-1.32%)	2.7M